1、Ginkgo Bioworks JP Morgan Conference 2024Property of Ginkgo Bioworks 1Grow with GinkgoJ.P.Morgan Healthcare ConferenceJason KellyCo-Founder&CEOJanuary 10,20241Ginkgo Bioworks JP Morgan Conference 2024Property of Ginkgo Bioworks 2Forward-Looking StatementsThis presentation,the conference call and web

2、cast(together,the“presentation”)contain certain forward-looking statements within the meaning of the federal securities laws,including statements regarding our plans and strategies,including with respect to our balance sheet and cash runway,current expectations,operations and anticipated results of

3、operations,both business and financial,including opportunities for increased operational efficiency,growth of pharmaceutical partnerships,potential customer success,including successful application of our offerings by our customers,expectations with regard to revenue,and the market environment,all o

4、f which are subject to known and unknown risks,uncertainties and other factors that may cause our actual results,performance or achievements,market trends,or industry results to differ materially from those expressed or implied by such forward-looking statements.These forward-looking statements gene

5、rally are identified by the words believe,can,project,potential,expect,anticipate,estimate,intend,strategy,future,opportunity,plan,may,should,will,would,will be,will continue,will likely result,and similar expressions.Forward-looking statements are predictions,projections and other statements about

6、future events that are based on current expectations and assumptions and,as a result,are subject to risks and uncertainties.Many factors could cause actual future events to differ materially from the forward-looking statements in this presentation,including but not limited to:(i)volatility in the pr

7、ice of Ginkgos securities due to a variety of factors,including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate,variations in performance across competitors,and changes in laws and regulations affecting Ginkgos business,(ii)the ability to impl

8、ement business plans,forecasts,and other expectations,and to identify and realize additional business opportunities,(iii)the risk of downturns in demand for products using synthetic biology,(iv)the uncertainty regarding the demand for passive monitoring programs and biosecurity services,(v)changes t

9、o the biosecurity industry,including due to advancements in technology,emerging competition and evolution in industry demands,standards and regulations,(vi)our ability to realize the expected benefits of merger and acquisition transactions,(vii)the outcome of any legal proceedings against Ginkgo,inc

10、luding as a result of recent acquisitions,(viii)our ability to realize the expected benefits from and the success of our cell engineering platform programs,(ix)our ability to successfully develop engineered cells,bioprocesses,data packages or other deliverables,(x)the product development or commerci

11、alization success of our customers,(xi)our final audited revenue and other financial results may differ materially from the preliminary and unaudited amounts reported herein,and(xii)our final new program count,which is determined by the number of unique programs commenced within the reporting period

12、 based on a technical development plan or objective,may differ materially from the preliminary amounts reported herein.The foregoing list of factors is not exhaustive.You should carefully consider the foregoing factors and the other risks and uncertainties described in the Risk Factors section of Gi

13、nkgos most recent quarterly report on Form 10-Q filed with the U.S.Securities and Exchange Commission(the SEC),and other documents filed by Ginkgo from time to time with the SEC.These filings identify and address other important risks and uncertainties that could cause actual events and results to d

14、iffer materially from those contained in the forward-looking statements.Forward-looking statements speak only as of the date they are made.Readers are cautioned not to put undue reliance on forward-looking statements,and Ginkgo assumes no obligation and does not intend to update or revise these forw

15、ard-looking statements,whether as a result of new information,future events,or otherwise.Ginkgo does not give any assurance that it will achieve its expectations.Industry and Market DataIn this presentation,Ginkgo relies on and refers to certain information and statistics regarding the markets and i

16、ndustries in which Ginkgo competes.Such information and statistics are based on Ginkgo managements estimates and/or obtained from third-party sources,including reports by market research firms and company filings.While Ginkgo believes such third-party information is reliable,there can be no assuranc

17、e as to the accuracy or completeness of the indicated information,and Ginkgo has not independently verified the accuracy or completeness of the information provided by the third-party sources.TrademarksThis presentation may contain trademarks,service marks,trade names and copyrights of other compani

18、es,which are the property of their respective owners,and Ginkgos use thereof does not imply an affiliation with,or endorsement by,the owners of such trademarks,service marks,trade names and copyrights.Solely for convenience,some of the trademarks,service marks,trade names and copyrights referred to

19、in this presentation may be listed without the TM,or symbols,but Ginkgo will assert,to the fullest extent under applicable law,the rights of the applicable owners,if any,to these trademarks,service marks,trade names and copyrights.Disclaimer2Ginkgo Bioworks JP Morgan Conference 2024Property of Ginkg

20、o Bioworks 3OUR MISSIONMake biology easier to engineerGinkgo Bioworks JP Morgan Conference 2024Property of Ginkgo Bioworks 4 Ended the year with nearly$950 million in cash and cash equivalents Reiterated full year 2023 revenue guidance expectations of$250-260 million Cell engineering:$145-150 millio

21、n Biosecurity:up to$110 million New cell programs are expected to be within the previously disclosed guidance range of 80-85 In 2024 we plan to continue increasing new programs while reducing operating expensesWe believe Ginkgos services business model allows a smoother path to profitability compare

22、d to traditional products-based biotechsPRELIMINARY UNAUDITED 2023 BUSINESS HIGHLIGHTSGinkgo Bioworks JP Morgan Conference 2024Property of Ginkgo Bioworks 5Merck,Ginkgo Bioworks strike deal worth up to$490M to optimize biologics manufacturing.FIERCE BIOTECH Aug.7,2023Successful completion of Biogen

23、collaboration focused on enhancing productivity of AAV production platform.GINKGO NEWS Jan.4,2024 Pfizer hooks up with Ginkgo for$331M biobucks deal on unspecified targets.FIERCE BIOTECH Sep.27,2023Busy dealmakers Ginkgo,Boehringer Ingelheim sign one together with$406M for undruggable targets.FIERCE

24、 BIOTECH May 8,2023Ginkgos achievement of the first milestone has both excited and inspired us,giving us the confidence to move into the next phase of this ambitious project.This progress is a strong indicator of the potential we have to engineer biological systems that will expand the chemical spac

25、e of biological medicines.BRIAN VANDAHLSVP,Global Research TechnologiesLEARN MORE2023 was an amazing year for Ginkgo services in the biopharma industryLEARN MORELEARN MORELEARN MORELEARN MOREGinkgo Bioworks JP Morgan Conference 2024Property of Ginkgo Bioworks 6Reported as current active programs2023

26、 was an amazing year for Ginkgo services in the biopharma industryOur pharma program mix doubledin the last two yearsPharma&BiotechCell Engineering-Pharma&Biotech Revenue1($M)50%in 2023Pharma&biotech revenue grew overGovernmentActive ProgramsPharma&BiotechFood&AgIndustrial&EnvironmentalConsumer&Tech

27、nology(1)Pharma&Biotech(“Biopharma”)revenue correlates to the portion of Ginkgo cell engineering revenue that is attributable to biopharma customersPreliminary unaudited estimateGinkgo Bioworks JP Morgan Conference 2024Property of Ginkgo Bioworks 7Figure is non-exhaustiveSmall MoleculeCell TherapyGe

28、ne TherapyRNA Tx&VaccinesBiologicsMicrobiomeInternal platform developmentLeading CGT platform companyMANUFACTURINGDISCOVERYSeveral confidential AAV capsid evaluationsLeading GeneTx companyGinkgo has biopharma customers across many modalities for both manufacturing and discovery R&DGinkgo Bioworks JP

29、 Morgan Conference 2024Property of Ginkgo Bioworks 8Recently announced Biopharma Advisory Board will provide critical insight into the development of Ginkgos core platform service offeringsNorbert BischofbergerKronos BioPresident&CEOJeff LegosNovartisEVP&Global Head of Oncology&HematologyJohn Maraga

30、noreAlnylamFormer CEO&DirectorPaolo MartiniModernaChief Scientific Officer of International Therapeutic Research Centers&Founder of Rare Diseases Mark McCamishIconOVir BioPresident&CEOChristi ShawBeam Therapeutics,ReAlta Life Sciences,and AvantorIndependent Director Ginkgo Bioworks JP Morgan Confere

31、nce 2024Property of Ginkgo Bioworks 9There are now five tech companies worth over$1 trillionAlso in 2023Market Cap($B)NVIDIA Joins$1 Trillion Club,fueled by AIs RiseJune 13,2023THE WALL STREET JOURNALApple Becomes First Company to Hit$3 Trillion Market ValueJan.3,2022THE NEW YORK TIMESAI Seen Fuelin

32、g Microsoft to$3 Trillion Value in Morgan Stanley ModelJul.6,2023BLOOMBERGAmazon Cloud Unit on Course for$3 Trillion Value,Redburn SaysJun.29,2022BLOOMBERGAlphabet Becomes Fourth U.S.Company to Reach$1 Trillion Market ValueJan.16,2020BLOOMBERG“Generative AI presents a new class of tools that will ge

33、t codified into applications and new methods of discovery.In fact,it will go beyond discovery and evolve into design,helping create the conditions to no longer be a hit or miss industry.And this will be what helps build the worlds first trillion-dollar drug company.”Kimberly PowellVP of Healthcare,N

34、VIDIAJanuary 8,2024Source:S&P Capital IQ as of 1/5/2024Ginkgo Bioworks JP Morgan Conference 2024Property of Ginkgo Bioworks 10Why arent there any trillion dollar companies in biopharma?$2,829$2,735$2,132$1,717$1,494$1,186$892$759$553$504TOP COMPANIES BY MARKET CAP($B)TOP PHARMA COMPANIES BY MARKET C

35、AP($B)$553$476$387$297$285$241$218$214$208$164$162$128$107$106$105$97$94$89$80$68$61$54KGaASource:S&P Capital IQ as of 1/5/202462Ginkgo Bioworks JP Morgan Conference 2024Property of Ginkgo Bioworks 11IDENTIFIED HUMAN DISEASES(1)5%95%Of the 10,000+known dis

36、eases,95%currently have no treatment available(1)As of April 2022,Source:National Institutes of Health(2)Iqvia Institute:The Global Use of Medicines 2023GLOBAL MEDICINE SPENDING($T)(2)DAILY DOSES(T)(2)The market is certainly big enoughGinkgo Bioworks JP Morgan Conference 2024Property of Ginkgo Biowo

37、rks 12New drugs per$BR&D(log scale)“I think there is a real opportunity for next gen technologies to improve the biggest challenge of the pharmaceutical sector,which is the productivity of R&D.It can take a decade,cost billions of dollars,on average has a 90%failure rate,to discover,develop and inve

38、nt new medicines and vaccines.Its the most profound challenge of our industry and also of society.When we talk about health care costs,the single biggest thing we can do is innovate more.”Emma WalmsleyCEO“At the outset,I want to be clear:We acknowledge the groundbreaking,lifesaving work that many ph

39、armaceutical companies are doingBut we can make a distinction between developing those breakthroughs and jacking up prices on a range of medicines,which have been on the market for years without making a substantial and a substantive change in the medicine itself.”President Joe BidenSources:The Biom

40、edical Bubble:Why UK research and innovation needs a greater diversity of priorities,politics,places and people,Nesta,July 2018;Why 90%of clinical drug development fails and how to improve it,Acta Pharmaceutica Sinica B,July 2022;Analysis of pharma R&D productivity-a new perspective needed,Drug Disc

41、overy Today,July 2023;GSK interview with Fortune,Fortune,June 2023;Remarks by President Joe Biden,the White House,December 2021Analyses of clinical trial data from 2010 to 2017 show four possible reasons attributed to the 90%clinical failures of drug development:lack of clinical efficacy(40%50%),unm

42、anageable toxicity(30%),poor drug-like properties(10%15%),and lack of commercial needs and poor strategic planning(10%)Pharma companies require constant new product launches but dont benefit from economies of scale in R&DAnalysis of pharma R&D productivity-a new perspective neededThe peer groups R&D

43、 efficiency(2001-2020)is$6.16 billion(total R&D spending per new drug launch)DRUG DISCOVERY TODAY Oct.28,2023Why 90%of clinical drug development fails and how to improve it?APSB Feb.11,2022Ginkgo Bioworks JP Morgan Conference 2024Property of Ginkgo Bioworks 13This issue is not unique to biopharma,bu

44、t to biotech in general.COST TO BRING A GENETIC TRAIT TO THE POINT OF COMMERCIALIZATION($M)1(1)Source:Time and Cost to Develop a New GM Trai(2)Current and former Ginkgo customersGinkgo Ag Customers2Each product is developed in a one-off process to improve odds of success.This variability prevents ec

45、onomies of scale in R&D.Ginkgo Bioworks JP Morgan Conference 2024Property of Ginkgo Bioworks 14Ginkgo believes there is a false choice between scale and flexibility.The commonalities in biotech work means you can have both.Biology is commonSource:All 2.3 Million Species Are Mapped into a Single Circ

46、le of Life,Scientific American,December 2016Lab equipment and reagents are common across all biotechGinkgo Bioworks JP Morgan Conference 2024Property of Ginkgo Bioworks 15Very early stageNot enough fundingIncentive to create new knowledge,not to develop platform techCapital constrained and asset cen

47、tricHave to focus on pipeline advancement rather than platform techLack culture of bleeding edge innovationBusiness model is selling mature R&D unit operations as a serviceNot enough breadth in the portfolio to make large investments in flexible platform techSome exceptions but few and far betweenAc

48、elyrin fails late-phase clinical trial months after$540M IPO,sending stock hurtling downwardNo one has solved this yet and current players arent positioned to invest the billions of dollars needed to develop a new technology stackACADEMIASMALL BIOTECHTRADITIONAL CROs LARGE PHARMA Crispr Surges After

49、 Winning the First-Ever Approval for a CRISPR-Based Gene-Editing DrugCROs and biotech companies:Fine-tuning the partnershipEmerging biotechnology companies are less satisfied than large pharmaceutical companies with their contract research organizations(CROs).How can CROs raise their game with this

50、key segment?Vertex Pharmaceuticals to acquire Aurora BiosciencesVertex to integrate Auroras core strengths in cell assay development and ultra high throughput screening to accelerate drug discovery in gene familiesGinkgo Bioworks JP Morgan Conference 2024Property of Ginkgo Bioworks 16 300,000 sq ft

51、of flexible automated wet labs and office space in Boston Proprietary automation suite and LIMS Massive proprietary collection of strains,metagenomic data(10 x UniProt),capsids,regulatory elements,ICDs,cell lines,and labeled assay data$250+million collaboration with Google Cloud Suite of AI models i

52、ntegrated into workflowsShared Infrastructure Investments at ScaleFlexible AutomationGinkgo has invested over$1 billion and over a decade developing a common technology stackData AssetsCompute+AI ModelsTask-specific modelsTrained with datasets of inputs and outputs to answer related questions Traine

53、d with large datasets(traditionally public databases with few“labels”)Learns general features of language,such as what it means to be“protein-like”.4Foundation ModelsGinkgo Bioworks JP Morgan Conference 2024Property of Ginkgo Bioworks 17Ginkgo develops proprietary automation systems in-house,as deli

54、vering flexibility at large scale is not available from traditional automation vendors The traditional lab automation continuum is limited by a tradeoff between flexibility and scaleManualIntegrated WorkcellsProprietary modular automation technology is flexible,extensible,extremely low-touch,and pro

55、vides rich data and metadata for partner programs,accelerating R&DMOST SCALEMOST FLEXIBILITYTask Targeted(“Walk Up”)Reconfigure in minutesScale to meet complexity123Reconfigurable Automation Carts(RACs)4Flexibility and Scale at onceGinkgo Bioworks JP Morgan Conference 2024Property of Ginkgo Bioworks

56、 18Ginkgos DNA and data assets are world classProprietary database for parts mining Database encompasses over 2 billion unique proteins and their associated sequences State-of-the-art,proprietary workflows for sequence mining Advanced computational tools to discover and optimize proteins,pathways,an

57、d cells200 unique customer programs with enzyme campaigns5Mtotal arrayed experimental assay tests60Mtotal multiplexed experimental assay tests400 unique enzyme improvement campaignsArrayed experimental sample tests of enzyme function,color coded by programFoundry-scale data generation capabilities i

58、n diverse systems enable discovery,product development,and AI model trainingOur library 2018Our library 2023UniProtKB/TrEMBL 2018UniProtKB/TrEMBL 2023246M genes100M genes2B+genes Including novel industrial enzymes,natural products,and other novel proteins139M genesGinkgo Bioworks JP Morgan Conferenc

59、e 2024Property of Ginkgo Bioworks 19Ginkgo asdasClass-Specific Enzyme Function(Catalysis)Foundation Model#1:Protein Foundation ModelSeveral iterations of model have been trained at pilot scales,testing:Impact of model size(point of diminishing returns)Impact of new data Methods for incorporating new

60、 data(handling diversity,multiple modalities,etc.)Even without implementing any novel model architectures or incorporating assay-labeled data,Ginkgos current foundation models match state-of-the-art public protein foundation model(ESM-2)on a like-for-like basis(same number of parameters)on ProteinGy

61、m(common benchmark)while significantly outperforming on protein classes less common in the public literatureBindingStabilityInverse FoldingExpressionSpecificityIP FreedomSolubilityand many more(including customized applications for customer programs)Ginkgo is investing over$250 million to train and

62、deploy state-of-the-art AI models for our customersAPPLICATIONSNEXT UP:scaling protein foundation model,launching DNA and RNA foundation models,and continuously launching new applicationsTHOMAS KURIANCEO“Our strategic partnership with Ginkgo is a first-of-its-kind for Google Cloud,underscoring our c

63、onfidence that Ginkgo will play a critical and pioneering role in the life sciences space,leveraging AI to reshape humanitys understanding of biology.”Ginkgo Bioworks JP Morgan Conference 2024Property of Ginkgo Bioworks 20AI-driven metagenomic discovery and closed loop engineering drives remarkable

64、multi-parameter resultsDiscovery of novel enzyme catalytic activity and improvement of multiple parameters in parallel for large pharma partnerSelectivity*(Normalized to WT enzyme 1 control)Activity(Normalized to WT enzyme 1 control)Variant enzyme 1Variant enzyme 2CLOSED LOOP ENGINEERING CYCLES Rein

65、forcement learning with lab feedback(“RLLF”)Engineered improved variants that optimized over three key outcomes in parallel(activity,selectivity,titer)3rd generation protein library demonstrated:110 x improvement in activity*21x improvement in selectivity*Gen2Gen1Gen3Metagenomic Search BaselineSelec

66、tivityActivity(or Productivity)*Vs.prioritized(blue)wild type template AI/ML METAGENOMIC SEARCH Discovery of better starting enzyme(s)for data-driven protein engineeringSourced and tested 1,000 variants from 183,000 candidate sequences based on sequence and structural models for improved productivit

67、y and selectivityPROTEIN ENGINEERING A portfolio of sequence and structural design tools applied to collectively select variantsFirst generation protein engineering library designed to maximize learning potential of AI/ML modelsIdentified variants with up to 5x improvement in activity and up to 14x

68、improvement in selectivity compared to two wild type templatesFLEXIBILITY AND SCALE IN ACTION:ENZYMES1Ginkgo Bioworks JP Morgan Conference 2024Property of Ginkgo Bioworks 21Same approach to train new AI/ML models towards circRNA programsThe tech stack and closed-loop systems applied to enzyme optimi

69、zationApplying sequence discovery and large scale data generation to RNA therapeutics discoverycircRNA introns with 90%circularization efficiency,significantly improved over state-of-the-art with no additional engineeringIRESs driving cell-type specific expressionRNA therapeutics are proving to be a

70、n important platform to advance the world of scientific innovation,and with progress in synthetic biology we have the potential to create new RNA treatments that may benefit patients worldwide.Access to Ginkgos proprietary platform will help enable Pfizer to search for novel and exciting RNA constru

71、cts with improved stability and expression that could lead to more effective treatments.Will SomersPH.D.,Head,Biomedicine DesignRecently announced Pfizer partnership is a good example of how Ginkgos unique scale&flexibility make us a leading innovation partner,even in new spaces.AI/ML METAGENOMIC SE

72、ARCHPROTEIN ENGINEERINGCLOSED-LOOP ENGINEERING CYCLESare directly applicable to developing circRNA therapeutics.AI and data-driven approach that can optimize enzymes can also be used to discover and develop sequence elements encoding circRNA therapeuticsFLEXIBILITY AND SCALE IN ACTION:RNA THERAPEUTI

73、CS2Effect on Translation OutputNumber of ConstructsGinkgo Bioworks JP Morgan Conference 2024Property of Ginkgo Bioworks 22A foundry-scale approach to developing novel intracellular signaling domains(ICDs)for T-cell and NK-cell therapyCombinatorial design and pooled screening identifies novel ICD com

74、binations across a variety of parametersFLEXIBILITY AND SCALE IN ACTION:CELL THERAPY3High affinity ECD to solid tumor antigenLow affinity ECD to solid tumor antigenICD 1ICD 2A common pooled ICD library was transducedinto T-cells for screeninginto NK-cells for screeningyielding ICDs with improved exh

75、austion&persistence profiles in T-cells.yielding ICD pairs showing strong immune activation in NK-cells.#ICD pairs enriching TNFa#ICD pairs enriching CD107a#ICD pairs enriching IFNyGinkgo Bioworks JP Morgan Conference 2024Property of Ginkgo Bioworks 23Hypothesis based on human geneticsDesign next se

76、t of perturbationsIntegrate data sources for analysisIdentify next set of perturbationsGene EditingGenerate Multi-omics data for analysisLeverage AI/ML for generating insightsWith AI,high throughput cell engineering and large scale data generation are poised to enable identification of new drug targ

77、ets1.Tam,V.,Patel,N.,Turcotte,M.et al.Benefits and limitations of genome-wide association studies.Nat Rev Genet 20,467484(2019).https:/doi.org/10.1038/s41576-019-0127-12.Ege,Nil,et al.Phenotypic screening with target identification and validation in the discovery and development of E3 ligase modulat

78、ors.Cell chemical biology 28.3(2021):283-299.3.Hingorani,A.D.,Kuan,V.,Finan,C.et al.Improving the odds of drug development success through human genomics:modelling study.Sci Rep 9,18911(2019).https:/doi.org/10.1038/s41598-019-54849-wTest Impact of cellular perturbationsCapabilities DevelopmentScale

79、of Data Generation(From 1K to 20K perturbations)Data IntegrationResource Prioritization“The fundamental problem in contemporary drug development has been the unreliability of target identification leading to low development success rates,inefficiency and escalating cost to healthcare users.Genomics

80、now provides a tool to address the problem directly by accurate identification of proteins that both play a controlling role in a disease and which are amenable to targeting by drugs.”-Improving the odds of drug development success through human genomics:modelling study3RedactedRedactedRedactedGinkg

81、o Bioworks JP Morgan Conference 2024Property of Ginkgo Bioworks 24One of the reasons the tech industry has been so successful is that these huge companies build on each otherEnabling tools and platforms with economies of scale can empower biotech giants.The commonality of DNA and lab work means it is possible,the industry just needs to evolve.Ginkgo Bioworks JP Morgan Conference 2024Property of Ginkgo Bioworks 25_Lets grow the world we want to